MENU
Aim higher

PNEUMONAV

A low-cost intranasal vaccine that offers universal protection against pneumococcal infections.

PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will consist of Outer Membrane Vesicles (OMVs), displaying fragments of novel conserved protein antigens. These antigens will warrant universal protection against all pneumococcal serotypes and can be delivered via intranasal administration. If successful, this next-generation vaccine will be able to decrease the incidence of pneumococcal diseases worldwide.
Acronym: 
PNEUMONAV
Project ID: 
9 285
Ranking: 
30
Cut-off: 
2
Start date: 
01-07-2015
Project Duration: 
38months
Project costs: 
1 971 360.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Drug delivery and other equipment (including kidney dialysis machines)